Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Новый пересмотр Европейских рекомендаций по диагностике и лечению артериальной гипертонии 2018 г.: важнейшие аспекты применения в реальной клинической практике
Остроумова О.Д., Кочетков А.И. Новый пересмотр Европейских рекомендаций по диагностике и лечению артериальной гипертонии 2018 г.: важнейшие аспекты применения в реальной клинической практике. Consilium Medicum. 2019; 21 (1): 9–16. DOI: 10.26442/20751753.2019.1.190183
________________________________________________
Ostroumova O.D., Kochetkov A.I. The new 2018 European guidelines for the management of arterial hypertension: the most important aspects of use in real-life clinical practice. Consilium Medicum. 2019; 21 (1): 9–16. DOI: 10.26442/20751753.2019.1.190183
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Представить основополагающие положения обновленных Европейских рекомендаций по диагностике и лечению артериальной гипертонии 2018 г. и обсудить особенности их применения в клинической практике, в том числе с учетом точки зрения российских экспертов.
Материалы и методы. Рассмотрены Европейские рекомендации по диагностике и лечению артериальной гипертонии 2018 г. и Меморандум экспертов Российского кардиологического общества по данному документу.Результаты и заключение. Описаны ключевые положения Европейских рекомендаций по диагностике и лечению артериальной гипертонии 2018 г., основополагающие и важные с точки зрения реальной клинической практики изменения в сравнении с предыдущим пересмотром. Большое внимание уделено вопросам выявления факторов риска и поражений органов, обусловленных гипертонией. Особый фокус сделан на доминирующий принцип медикаментозного контроля артериального давления (АД) – «стратегию одной таблетки», представлена пошаговая схема назначения комбинированной антигипертензивной терапии, препаратами 1-й линии которой являются блокаторы ренин-ангиотензин-альдостероновой системы (РААС). На первом этапе комбинация выбора – сочетание ингибитора ангиотензинпревращающего фермента или блокатора рецепторов ангиотензина II c дигидропиридиновым антагонистом кальция или диуретиком. Подчеркивается, что впервые в рекомендациях сделан акцент на применение трехкомпонентой антигипертензивной терапии также в форме одной таблетки и указаны конкретные ее компоненты (блокатор РААС, антагонист кальция и диуретик). Отмечена небольшая часть пациентов, у которых все-таки возможно применение антигипертензивных препаратов в виде монотерапии. Описана тактика ведения больных пожилого и очень пожилого возраста и лиц с синдромом старческой астении. Обсуждаются целевые уровни АД в зависимости от наличия сопутствующих заболеваний, таких как сахарный диабет, хроническая болезнь почек, ишемическая болезнь почек, инсульт и/или транзиторная ишемическая атака, и в зависимости от возраста пациента. Все позиции Европейских рекомендаций по артериальной гипертонии рассматриваются с точки зрения отечественных экспертов, которая представлена в Меморандуме Российского кардиологического общества. Во второй части статьи приведены возможности стратегии одной таблетки в комбинированной антигипертензивной терапии, основанной на валсартане, а также рассмотрена важность приверженности пациентов медикаментозному контролю АД и способы ее повышения.
Ключевые слова: артериальная гипертония, Европейские рекомендации, факторы риска, поражение органов, обусловленное гипертонией, стратегия одной таблетки, валсартан.
________________________________________________
Aim. To present the fundamental standpoints of renewed 2018 European guidelines for the management of arterial hypertension and to discuss aspects of its use in real-life clinical practice with due consideration of Russian experts opinions.
Materials and methods. 2018 European guidelines for the management of arterial hypertension and Russian Society of Cardiology Memorandum on these guidelines are discussed.Results and conclusion. Fundamental standpoints of 2018 European guidelines for the management of arterial hypertension as well as essential and important in context of real-life clinical practice changes in comparison with the previous revision are presented. Much attention is given to risk factors and associated with hypertension organ damage detection. Special focus is made on the main principle of blood pressure pharmacological control – “one pill strategy”. A step to step regimen for prescription of combined antihypertensive therapy where renin angiotensin aldosterone system (RAAS) inhibitors are first line medications is presented. At the first stage the choice combination includes angiotensin-converting-enzyme inhibitor or angiotensin II receptor blocker and dihydropyridine calcium channel blocker or diuretic. It is outlined that for the first time in the guidelines the use of 3-component antihypertensive therapy in the form of “one pill” is emphasized and its actual components are specified (RAAS inhibitor, calcium channel blocker and diuretic). Also a small subset of patients in whom it is possible to use antihypertensive medications in monotherapy is described. The management of elderly and very elderly patients and patients with senile asthenia syndrome is described. Target blood pressure levels depending on comorbid disorders existence such as diabetes mellitus, chronic kidney disease, ischemic kidney disease, stroke and/or transient ischemic attack as well as patient age are discussed. All standpoints of European guidelines for the management of arterial hypertension are discussed from the point of view of Russian experts that is presented in Russian Society of Cardiology Memorandum. The second part of the article presents possibilities of one pill strategy use in combined antihypertensive therapy based of valsartan and discusses the importance of patients’ compliance to blood pressure pharmacological control and ways of improving this compliance.
Key words: arterial hypertension, European guidelines, risk factors, organs involvement, associated with hypertension, one pill strategy, valsartan.
Полный текст
Список литературы
1. Williams B, Mancia G, Spiering W et al; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018; 39 (33): 3021–104. DOI: 10.1093/eurheartj/ehy339
2. Кобалава Ж.Д., Конради А.О., Недогода С.В. и др. Меморандум экспертов Российского кардиологического общества по рекомендациям Европейского общества кардиологов/Европейского общества по артериальной гипертензии по лечению артериальной гипертензии 2018 г. Рос. кардиол. журн. 2018; 23 (12): 131–42. DOI: 10.15829/1560-4071-2018-12-131-14
[Kobalava Zh.D., Konradi A.O., Nedogoda S.V. et al. Memorandum ekspertov Rossiiskogo kardiologicheskogo obshchestva po rekomendatsiiam Evropeiskogo obshchestva kardiologov/Evropeiskogo obshchestva po arterial'noi gipertenzii po lecheniiu arterial'noi gipertenzii 2018 g. Ros. kardiol. zhurn. 2018; 23 (12): 131–42. DOI: 10.15829/1560-4071-2018-12-131-14 (in Russian).]
3. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993; 27: 341–8.
4. Fisher JP, Paton JF. The sympathetic nervous system and blood pressure in humans: implications for hypertension. J Hum Hypertens 2012; 26 (8): 463–75.
5. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357. DOI: 10.1097/01.hjh.0000431740.32696.cc
6. Van Sloten TT, Stehouwer CD. Carotid Stiffness: A Novel Cerebrovascular Disease Risk Factor. Pulse (Basel) 2016; 4 (1): 24–7. DOI: 10.1159/000445354
7. Laurent S, Katsahian S, Fassot C et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003; 34 (5): 1203–6. DOI: 10.1161/01.STR.0000065428.03209.64
8. Laurent S, Boutouyrie P, Asmar R et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236–41.
9. Kullo IJ, Bielak LF, Turner ST et al. Aortic pulse wave velocity is associated with the presence and quantity of coronary artery calcium: a community-based study. Hypertension 2006; 47 (2): 174–9. DOI: 10.1161/01.HYP.0000199605.35173.14
10. Corrao G, Mazzola P, Monzio Compagnoni M et al. Antihypertensive medications, loop diuretics, and risk of hip fracture in the elderly: a population-based cohort study of 81.617 Italian patients newly treated between 2005 and 2009. Drugs Aging 2015; 32: 927–36.
11. Kjeldsen SE, Stenehjem A, Os I et al. Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets. Blood Press 2016; 25: 333–6.
12. Galzerano D, Capogrosso C, Di Michele S et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag 2010; 6: 113–33.
13. Максимов М.Л., Ермолаева А.С., Дралова О.В. Когда назначать валсартан? Применение блокатора рецепторов ангиотензина валсартана в фармакотерапии сердечно-сосудистых заболеваний. Артериальная гипертензия. 2013; 19 (5): 458–71.
[Maksimov M.L., Ermolaeva A.S., Dralova O.V. Kogda naznachat' valsartan? Primenenie blokatora retseptorov angiotenzina valsartana v farmakoterapii serdechno-sosudistykh zabolevanii. Arterial'naia gipertenziia. 2013; 19 (5): 458–71 (in Russian).]
14. Остроумова О.Д., Гусева Т.Ф., Шорикова Е.Г. Применение препарата Вальсакор® при артериальной гипертонии: результаты словенского многоцентрового исследования. Рус. мед. журн. 2010; 18 (2): 642.
[Ostroumova O.D., Guseva T.F., Shorikova E.G. Primenenie preparata Val'sakor® pri arterial'noi gipertonii: rezul'taty slovenskogo mnogotsentrovogo issledovaniia. Rus. med. zhurn. 2010; 18 (2): 642 (in Russian).]
15. Yusuf S, Hawken S, Ounpuu S et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364 (9438): 937–52. DOI: 10.1016/S0140-6736(04)17018-9
16. Rapsomaniki E, Timmis A, George J et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 2014; 383 (9932): 1899–911. DOI: 10.1016/S0140-6736(14)60685-1
17. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387 (10022): 957–67. DOI: 10.1016/S0140-6736(15)01225-8
18. McMurray J, Solomon S, Pieper K et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006; 47 (4): 726–33.
19. Maggioni AP, Latini R, Carson PE et al; Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149 (3): 548–57.
20. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345 (23): 1667–75.
21. Чазова И.Е., Мартынюк Т.В., Accetto R и др. Итоги международного клинического исследования VICTORY: эффективность и безопасность антигипертензивной монотерапии валсартаном (Вальсакор®) и его фиксированной комбинации с гидрохлоротиазидом (Вальсакор® Н) у пациентов с артериальной гипертонией 1–2-й степени. Системные гипертензии. 2017; 14 (2): 80–9. DOI: 10.26442/2075-082X_14.2.80-89
[Chazova I.E., Martynyuk T.V., Accetto R. et al. The results of the international clinical study VICTORY: efficacy and safety of antihypertensive monotherapy with valsartan (Valsacor®) and its fixed combination with hydrochlorothiazide (Valsacor® H) in routine clinical practice in patients with grade 1 and grade 2 hypertension. Systemic Hypertension. 2017; 14 (2): 80–9. DOI: 10.26442/2075-082X_14.2.80-89 (in Russian).]
22. Чазова И.Е., Мартынюк Т.В., Accetto R. и др. Влияние антигипертензивной терапии валсартаном и его фиксированной комбинации с гидрохлоротиазидом на скорость пульсовой волны и центральное артериальное давление у пациентов с артериальной гипертонией 1–2-й степени по результатам международного клинического исследования VICTORY. Системные гипертензии. 2018; 15 (2): 6–13. DOI: 10.26442/2075-082X_2018.2.6-13.
[Chazova I.E., Martynyuk T.V., Accetto R. et al. The influence of antyhypertensive therapy of valsartan and fixed combination with hydrochlorothiazide use on pulse-wave velocity and central arterial pressure in patients with arterial hypertension of 1-2 stages in international VICTORY clinical trial. Systemic Hypertension. 2018; 15 (2): 6–13. DOI: 10.26442/2075-082X_2018.2.6-13 (in Russian).]
23. Борисова Е.В., Кочетков А.И., Остроумова О.Д. Влияние фиксированной комбинации валсартан/амлодипин на уровень артериального давления и параметры жесткости сосудов у пациентов с эссенциальной гипертонией 1–2 степени. Рациональная фармакотерапия в кардиологии. 2018; 14 (6): 831–9. DOI: 10.20996/1819-6446-2018-14-6-831-839
[Borisova E.V., Kochetkov A.I., Ostroumova O.D. Vliianie fiksirovannoi kombinatsii valsartan/amlodipin na uroven' arterial'nogo davleniia i parametry zhestkosti sosudov u patsientov s essentsial'noi gipertoniei 1–2 stepeni. Ratsional'naia farmakoterapiia v kardiologii. 2018; 14 (6): 831–9. DOI: 10.20996/1819-6446-2018-14-6-831-839 (in Russian).]
24. Assaad-Khalil SH, Najem R, Sison J et al. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups. Vasc Health Risk Management 2015; 11: 71–8. DOI: 10.2147/VHRM.S76599
25. Hagendorff A, Kurz I, Müller A, Klebs S. Evaluation of effectiveness and safety of amlodipine/valsartan/hydrochlorothiazide single-pill combination therapy in hypertensive patients: an observational study. J Drug Assess 2014; 3 (1): 1–9. DOI: 10.3109/21556660.2014.884506
3. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993; 27: 341–8.
4. Fisher JP, Paton JF. The sympathetic nervous system and blood pressure in humans: implications for hypertension. J Hum Hypertens 2012; 26 (8): 463–75.
5. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357. DOI: 10.1097/01.hjh.0000431740.32696.cc
6. Van Sloten TT, Stehouwer CD. Carotid Stiffness: A Novel Cerebrovascular Disease Risk Factor. Pulse (Basel) 2016; 4 (1): 24–7. DOI: 10.1159/000445354
7. Laurent S, Katsahian S, Fassot C et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003; 34 (5): 1203–6. DOI: 10.1161/01.STR.0000065428.03209.64
8. Laurent S, Boutouyrie P, Asmar R et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236–41.
9. Kullo IJ, Bielak LF, Turner ST et al. Aortic pulse wave velocity is associated with the presence and quantity of coronary artery calcium: a community-based study. Hypertension 2006; 47 (2): 174–9. DOI: 10.1161/01.HYP.0000199605.35173.14
10. Corrao G, Mazzola P, Monzio Compagnoni M et al. Antihypertensive medications, loop diuretics, and risk of hip fracture in the elderly: a population-based cohort study of 81.617 Italian patients newly treated between 2005 and 2009. Drugs Aging 2015; 32: 927–36.
11. Kjeldsen SE, Stenehjem A, Os I et al. Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets. Blood Press 2016; 25: 333–6.
12. Galzerano D, Capogrosso C, Di Michele S et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag 2010; 6: 113–33.
13. Maksimov M.L., Ermolaeva A.S., Dralova O.V. Kogda naznachat' valsartan? Primenenie blokatora retseptorov angiotenzina valsartana v farmakoterapii serdechno-sosudistykh zabolevanii. Arterial'naia gipertenziia. 2013; 19 (5): 458–71 (in Russian).
14. Ostroumova O.D., Guseva T.F., Shorikova E.G. Primenenie preparata Val'sakor® pri arterial'noi gipertonii: rezul'taty slovenskogo mnogotsentrovogo issledovaniia. Rus. med. zhurn. 2010; 18 (2): 642 (in Russian).
15. Yusuf S, Hawken S, Ounpuu S et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364 (9438): 937–52. DOI: 10.1016/S0140-6736(04)17018-9
16. Rapsomaniki E, Timmis A, George J et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 2014; 383 (9932): 1899–911. DOI: 10.1016/S0140-6736(14)60685-1
17. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387 (10022): 957–67. DOI: 10.1016/S0140-6736(15)01225-8
18. McMurray J, Solomon S, Pieper K et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006; 47 (4): 726–33.
19. Maggioni AP, Latini R, Carson PE et al; Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149 (3): 548–57.
20. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345 (23): 1667–75.
21. Chazova I.E., Martynyuk T.V., Accetto R. et al. The results of the international clinical study VICTORY: efficacy and safety of antihypertensive monotherapy with valsartan (Valsacor®) and its fixed combination with hydrochlorothiazide (Valsacor® H) in routine clinical practice in patients with grade 1 and grade 2 hypertension. Systemic Hypertension. 2017; 14 (2): 80–9. DOI: 10.26442/2075-082X_14.2.80-89 (in Russian).
22. Chazova I.E., Martynyuk T.V., Accetto R. et al. The influence of antyhypertensive therapy of valsartan and fixed combination with hydrochlorothiazide use on pulse-wave velocity and central arterial pressure in patients with arterial hypertension of 1-2 stages in international VICTORY clinical trial. Systemic Hypertension. 2018; 15 (2): 6–13. DOI: 10.26442/2075-082X_2018.2.6-13 (in Russian).
23. Borisova E.V., Kochetkov A.I., Ostroumova O.D. Vliianie fiksirovannoi kombinatsii valsartan/amlodipin na uroven' arterial'nogo davleniia i parametry zhestkosti sosudov u patsientov s essentsial'noi gipertoniei 1–2 stepeni. Ratsional'naia farmakoterapiia v kardiologii. 2018; 14 (6): 831–9. DOI: 10.20996/1819-6446-2018-14-6-831-839 (in Russian).
24. Assaad-Khalil SH, Najem R, Sison J et al. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups. Vasc Health Risk Management 2015; 11: 71–8. DOI: 10.2147/VHRM.S76599
25. Hagendorff A, Kurz I, Müller A, Klebs S. Evaluation of effectiveness and safety of amlodipine/valsartan/hydrochlorothiazide single-pill combination therapy in hypertensive patients: an observational study. J Drug Assess 2014; 3 (1): 1–9. DOI: 10.3109/21556660.2014.884506
2. Кобалава Ж.Д., Конради А.О., Недогода С.В. и др. Меморандум экспертов Российского кардиологического общества по рекомендациям Европейского общества кардиологов/Европейского общества по артериальной гипертензии по лечению артериальной гипертензии 2018 г. Рос. кардиол. журн. 2018; 23 (12): 131–42. DOI: 10.15829/1560-4071-2018-12-131-14
[Kobalava Zh.D., Konradi A.O., Nedogoda S.V. et al. Memorandum ekspertov Rossiiskogo kardiologicheskogo obshchestva po rekomendatsiiam Evropeiskogo obshchestva kardiologov/Evropeiskogo obshchestva po arterial'noi gipertenzii po lecheniiu arterial'noi gipertenzii 2018 g. Ros. kardiol. zhurn. 2018; 23 (12): 131–42. DOI: 10.15829/1560-4071-2018-12-131-14 (in Russian).]
3. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993; 27: 341–8.
4. Fisher JP, Paton JF. The sympathetic nervous system and blood pressure in humans: implications for hypertension. J Hum Hypertens 2012; 26 (8): 463–75.
5. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357. DOI: 10.1097/01.hjh.0000431740.32696.cc
6. Van Sloten TT, Stehouwer CD. Carotid Stiffness: A Novel Cerebrovascular Disease Risk Factor. Pulse (Basel) 2016; 4 (1): 24–7. DOI: 10.1159/000445354
7. Laurent S, Katsahian S, Fassot C et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003; 34 (5): 1203–6. DOI: 10.1161/01.STR.0000065428.03209.64
8. Laurent S, Boutouyrie P, Asmar R et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236–41.
9. Kullo IJ, Bielak LF, Turner ST et al. Aortic pulse wave velocity is associated with the presence and quantity of coronary artery calcium: a community-based study. Hypertension 2006; 47 (2): 174–9. DOI: 10.1161/01.HYP.0000199605.35173.14
10. Corrao G, Mazzola P, Monzio Compagnoni M et al. Antihypertensive medications, loop diuretics, and risk of hip fracture in the elderly: a population-based cohort study of 81.617 Italian patients newly treated between 2005 and 2009. Drugs Aging 2015; 32: 927–36.
11. Kjeldsen SE, Stenehjem A, Os I et al. Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets. Blood Press 2016; 25: 333–6.
12. Galzerano D, Capogrosso C, Di Michele S et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag 2010; 6: 113–33.
13. Максимов М.Л., Ермолаева А.С., Дралова О.В. Когда назначать валсартан? Применение блокатора рецепторов ангиотензина валсартана в фармакотерапии сердечно-сосудистых заболеваний. Артериальная гипертензия. 2013; 19 (5): 458–71.
[Maksimov M.L., Ermolaeva A.S., Dralova O.V. Kogda naznachat' valsartan? Primenenie blokatora retseptorov angiotenzina valsartana v farmakoterapii serdechno-sosudistykh zabolevanii. Arterial'naia gipertenziia. 2013; 19 (5): 458–71 (in Russian).]
14. Остроумова О.Д., Гусева Т.Ф., Шорикова Е.Г. Применение препарата Вальсакор® при артериальной гипертонии: результаты словенского многоцентрового исследования. Рус. мед. журн. 2010; 18 (2): 642.
[Ostroumova O.D., Guseva T.F., Shorikova E.G. Primenenie preparata Val'sakor® pri arterial'noi gipertonii: rezul'taty slovenskogo mnogotsentrovogo issledovaniia. Rus. med. zhurn. 2010; 18 (2): 642 (in Russian).]
15. Yusuf S, Hawken S, Ounpuu S et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364 (9438): 937–52. DOI: 10.1016/S0140-6736(04)17018-9
16. Rapsomaniki E, Timmis A, George J et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 2014; 383 (9932): 1899–911. DOI: 10.1016/S0140-6736(14)60685-1
17. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387 (10022): 957–67. DOI: 10.1016/S0140-6736(15)01225-8
18. McMurray J, Solomon S, Pieper K et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006; 47 (4): 726–33.
19. Maggioni AP, Latini R, Carson PE et al; Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149 (3): 548–57.
20. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345 (23): 1667–75.
21. Чазова И.Е., Мартынюк Т.В., Accetto R и др. Итоги международного клинического исследования VICTORY: эффективность и безопасность антигипертензивной монотерапии валсартаном (Вальсакор®) и его фиксированной комбинации с гидрохлоротиазидом (Вальсакор® Н) у пациентов с артериальной гипертонией 1–2-й степени. Системные гипертензии. 2017; 14 (2): 80–9. DOI: 10.26442/2075-082X_14.2.80-89
[Chazova I.E., Martynyuk T.V., Accetto R. et al. The results of the international clinical study VICTORY: efficacy and safety of antihypertensive monotherapy with valsartan (Valsacor®) and its fixed combination with hydrochlorothiazide (Valsacor® H) in routine clinical practice in patients with grade 1 and grade 2 hypertension. Systemic Hypertension. 2017; 14 (2): 80–9. DOI: 10.26442/2075-082X_14.2.80-89 (in Russian).]
22. Чазова И.Е., Мартынюк Т.В., Accetto R. и др. Влияние антигипертензивной терапии валсартаном и его фиксированной комбинации с гидрохлоротиазидом на скорость пульсовой волны и центральное артериальное давление у пациентов с артериальной гипертонией 1–2-й степени по результатам международного клинического исследования VICTORY. Системные гипертензии. 2018; 15 (2): 6–13. DOI: 10.26442/2075-082X_2018.2.6-13.
[Chazova I.E., Martynyuk T.V., Accetto R. et al. The influence of antyhypertensive therapy of valsartan and fixed combination with hydrochlorothiazide use on pulse-wave velocity and central arterial pressure in patients with arterial hypertension of 1-2 stages in international VICTORY clinical trial. Systemic Hypertension. 2018; 15 (2): 6–13. DOI: 10.26442/2075-082X_2018.2.6-13 (in Russian).]
23. Борисова Е.В., Кочетков А.И., Остроумова О.Д. Влияние фиксированной комбинации валсартан/амлодипин на уровень артериального давления и параметры жесткости сосудов у пациентов с эссенциальной гипертонией 1–2 степени. Рациональная фармакотерапия в кардиологии. 2018; 14 (6): 831–9. DOI: 10.20996/1819-6446-2018-14-6-831-839
[Borisova E.V., Kochetkov A.I., Ostroumova O.D. Vliianie fiksirovannoi kombinatsii valsartan/amlodipin na uroven' arterial'nogo davleniia i parametry zhestkosti sosudov u patsientov s essentsial'noi gipertoniei 1–2 stepeni. Ratsional'naia farmakoterapiia v kardiologii. 2018; 14 (6): 831–9. DOI: 10.20996/1819-6446-2018-14-6-831-839 (in Russian).]
24. Assaad-Khalil SH, Najem R, Sison J et al. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups. Vasc Health Risk Management 2015; 11: 71–8. DOI: 10.2147/VHRM.S76599
25. Hagendorff A, Kurz I, Müller A, Klebs S. Evaluation of effectiveness and safety of amlodipine/valsartan/hydrochlorothiazide single-pill combination therapy in hypertensive patients: an observational study. J Drug Assess 2014; 3 (1): 1–9. DOI: 10.3109/21556660.2014.884506
________________________________________________
1. Williams B, Mancia G, Spiering W et al; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018; 39 (33): 3021–104. DOI: 10.1093/eurheartj/ehy339
2. Kobalava Zh.D., Konradi A.O., Nedogoda S.V. et al. Memorandum ekspertov Rossiiskogo kardiologicheskogo obshchestva po rekomendatsiiam Evropeiskogo obshchestva kardiologov/Evropeiskogo obshchestva po arterial'noi gipertenzii po lecheniiu arterial'noi gipertenzii 2018 g. Ros. kardiol. zhurn. 2018; 23 (12): 131–42. DOI: 10.15829/1560-4071-2018-12-131-14 (in Russian).3. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993; 27: 341–8.
4. Fisher JP, Paton JF. The sympathetic nervous system and blood pressure in humans: implications for hypertension. J Hum Hypertens 2012; 26 (8): 463–75.
5. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357. DOI: 10.1097/01.hjh.0000431740.32696.cc
6. Van Sloten TT, Stehouwer CD. Carotid Stiffness: A Novel Cerebrovascular Disease Risk Factor. Pulse (Basel) 2016; 4 (1): 24–7. DOI: 10.1159/000445354
7. Laurent S, Katsahian S, Fassot C et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003; 34 (5): 1203–6. DOI: 10.1161/01.STR.0000065428.03209.64
8. Laurent S, Boutouyrie P, Asmar R et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236–41.
9. Kullo IJ, Bielak LF, Turner ST et al. Aortic pulse wave velocity is associated with the presence and quantity of coronary artery calcium: a community-based study. Hypertension 2006; 47 (2): 174–9. DOI: 10.1161/01.HYP.0000199605.35173.14
10. Corrao G, Mazzola P, Monzio Compagnoni M et al. Antihypertensive medications, loop diuretics, and risk of hip fracture in the elderly: a population-based cohort study of 81.617 Italian patients newly treated between 2005 and 2009. Drugs Aging 2015; 32: 927–36.
11. Kjeldsen SE, Stenehjem A, Os I et al. Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets. Blood Press 2016; 25: 333–6.
12. Galzerano D, Capogrosso C, Di Michele S et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag 2010; 6: 113–33.
13. Maksimov M.L., Ermolaeva A.S., Dralova O.V. Kogda naznachat' valsartan? Primenenie blokatora retseptorov angiotenzina valsartana v farmakoterapii serdechno-sosudistykh zabolevanii. Arterial'naia gipertenziia. 2013; 19 (5): 458–71 (in Russian).
14. Ostroumova O.D., Guseva T.F., Shorikova E.G. Primenenie preparata Val'sakor® pri arterial'noi gipertonii: rezul'taty slovenskogo mnogotsentrovogo issledovaniia. Rus. med. zhurn. 2010; 18 (2): 642 (in Russian).
15. Yusuf S, Hawken S, Ounpuu S et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364 (9438): 937–52. DOI: 10.1016/S0140-6736(04)17018-9
16. Rapsomaniki E, Timmis A, George J et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 2014; 383 (9932): 1899–911. DOI: 10.1016/S0140-6736(14)60685-1
17. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387 (10022): 957–67. DOI: 10.1016/S0140-6736(15)01225-8
18. McMurray J, Solomon S, Pieper K et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006; 47 (4): 726–33.
19. Maggioni AP, Latini R, Carson PE et al; Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149 (3): 548–57.
20. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345 (23): 1667–75.
21. Chazova I.E., Martynyuk T.V., Accetto R. et al. The results of the international clinical study VICTORY: efficacy and safety of antihypertensive monotherapy with valsartan (Valsacor®) and its fixed combination with hydrochlorothiazide (Valsacor® H) in routine clinical practice in patients with grade 1 and grade 2 hypertension. Systemic Hypertension. 2017; 14 (2): 80–9. DOI: 10.26442/2075-082X_14.2.80-89 (in Russian).
22. Chazova I.E., Martynyuk T.V., Accetto R. et al. The influence of antyhypertensive therapy of valsartan and fixed combination with hydrochlorothiazide use on pulse-wave velocity and central arterial pressure in patients with arterial hypertension of 1-2 stages in international VICTORY clinical trial. Systemic Hypertension. 2018; 15 (2): 6–13. DOI: 10.26442/2075-082X_2018.2.6-13 (in Russian).
23. Borisova E.V., Kochetkov A.I., Ostroumova O.D. Vliianie fiksirovannoi kombinatsii valsartan/amlodipin na uroven' arterial'nogo davleniia i parametry zhestkosti sosudov u patsientov s essentsial'noi gipertoniei 1–2 stepeni. Ratsional'naia farmakoterapiia v kardiologii. 2018; 14 (6): 831–9. DOI: 10.20996/1819-6446-2018-14-6-831-839 (in Russian).
24. Assaad-Khalil SH, Najem R, Sison J et al. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups. Vasc Health Risk Management 2015; 11: 71–8. DOI: 10.2147/VHRM.S76599
25. Hagendorff A, Kurz I, Müller A, Klebs S. Evaluation of effectiveness and safety of amlodipine/valsartan/hydrochlorothiazide single-pill combination therapy in hypertensive patients: an observational study. J Drug Assess 2014; 3 (1): 1–9. DOI: 10.3109/21556660.2014.884506
Авторы
О.Д.Остроумова*, А.И.Кочетков
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России – ОСП «Российский геронтологический научно-клинический центр». 129226, Россия, Москва, ул. 1-я Леонова, д. 16
*ostroumova.olga@mail.ru
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России – ОСП «Российский геронтологический научно-клинический центр». 129226, Россия, Москва, ул. 1-я Леонова, д. 16
*ostroumova.olga@mail.ru
________________________________________________
Olga D. Ostroumova*, Aleksei I. Kochetkov
N.I.Pirogov National Medical and Surgical Center of the Ministry of Health of the Russian Federation – Russian Clinical and Research Center of Gerontology. 16, 1-ia Leonova st., Moscow, 129226, Russian Federation
*ostroumova.olga@mail.ru
N.I.Pirogov National Medical and Surgical Center of the Ministry of Health of the Russian Federation – Russian Clinical and Research Center of Gerontology. 16, 1-ia Leonova st., Moscow, 129226, Russian Federation
*ostroumova.olga@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.